Emmyon, INC.
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $3.0Mattributed |
|---|---|
| Latest round | strategic, $2.0M, 2025-01-01attributed |
| Founded | 2013 |
| Headquarters | Rochester, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | emmyon.com |
Emmyon develops biopharmaceuticals targeting age-related muscle decline (sarcopenia) and cancer-related cachexia. It serves geriatric patients and oncology patients losing muscle mass and function. Its small-molecule muscle-anabolic mechanism is a pathway that GLP-1 and existing oncology drugs leave untreated.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | strategic | $2.0M | undisclosed |
Detected tech stack
Google Analytics, Google Tag Manager, Sucuri, jQuery Migrate 3.4.1, DoubleClick Floodlight, OWL Carousel, WordPress, Bluehost, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | emmyon.com, read 2026-05-02 |
| Description | self-reported | emmyon.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.